TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06538480: Zopa Retreatment and Vector Shedding in Adults With RRP

Sponsor: Precigen, Inc · Phase: PHASE4 · Area: INFECTIOUS_VACCINE · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$517,440

Rescue Site Savings

+$352,800

Unlock Full NCT06538480 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06538480 Rescue Dossier →